Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
We offer a range of high-quality Claudin6 CAR-related products and services that are instrumental in the design, development, and evaluation of CAR therapies targeting Claudin6. Please refer to the following items to choose the appropriate products that you desire.
Claudin6 is a protein that belongs to the claudin family, which are integral membrane proteins that play a critical role in the formation of tight junctions between cells. Tight junctions are specialized structures that seal the spaces between cells, regulating the passage of ions and molecules across cell layers. Claudin6 is specifically involved in the regulation of paracellular permeability in epithelial and endothelial cells, helping to maintain the barrier function of tissues and organs. Aberrant expression of claudin-6 has been associated with various diseases, including liver, ovarian, endometrial, and oesophageal cancer, and atypical teratoid/rhabdoid tumors. Featured with its crucial biological functions, Claudin6 has emerged as an attractive therapeutic target for many cancers.
Fig.1 qPCR expression test of Claudin6 transcripts in human normal tissues and ovarian cancer.1
Associated Diseases
To accelerate CART development, we offer a range of custom service solutions to facilitate the development of personalized CAR-T cell therapies. Our services include:
Creative Biolabs specializes in designing CAR constructs tailored to target specific antigens expressed by cancer cells, including classical CAR design, armored CAR constructions, etc. Our team of experts custom CAR structure with optimized binding affinities and signaling domains to enhance treatment efficacy.
Fig.2 Schematic diagram of Claudin6 CAR construction.1
For the CART expression test, Creative Biolabs has launched many sensitive CAR detection reagents (e.g., antigen-specific detection reagents, and universal reagents like anti-mouse/human Fab antibodies). In addition, we offer CAR expression detection services utilizing comprehensive techniques to accurately assess CAR expression levels.
Analyzing the expansion and proliferation of CAR T cells in vitro will provide valuable insights into their function and potential for therapeutic applications. Creative Biolabs is dedicated to providing CART proliferation tests with several approaches (e.g., CFSE-based proliferation test, CCK-8 assay, MTT assay) to meet specific client needs, accommodating different types of CAR constructs, antigens, and cell types to ensure a precise and comprehensive evaluation.
Fig.3 Proliferation test of Claudin6 CAR-transduced T cells detected by flow cytometry after 5 days.1
Cytokine release test is a vital tool for evaluating the performance and efficacy of CAR-T cells against target cells. Our services include utilizing several techniques like Enzyme-Linked Immunosorbent Assay (ELISA), multiplex bead arrays, and intracellular cytokine analysis by flow cytometry to measure and analyze the cytokine release profile.
Fig.4 Cytokine detection of Claudin6-CART cells co-culture with claudin-expressing DCs analyzed by a multiplex assay.1
CART cell in vitro cytotoxicity assay is a widely used technique to assess the killing capability of CAR-T cells toward target cells. We offer several methods to analyze the cytotoxicity of CAR-T cells, such as the flow cytometry-based assay, chromium release assay, and luminescence-based assay.
Fig.5 In vitro dynamic killing assessment of Claudin6 CAR-T cells against Claudin6 positive tumor spheroids at 10:1 E:T ratio.1
More importantly, Creative Biolabs offers comprehensive CART in vivo study services, which involve the use of appropriate animal models to assess the efficacy and functionality of CAR-T cells in vivo, offering important data for evaluating the therapeutic potential of CAR-T cell therapies in a preclinical setting.
Fig.6 In vivo efficacy of anti-Claudin6 CAR-T in Claudin6 expressing OV90 cell CDX model. Claudin6 expressing OV90 cells and CART cell characteristics (left and middle) and tumor growth kinetics of CDX model (right) were analyzed.1
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| XS-0622-ZP3387 | Anti-Claudin 6 h(VHH1-VHH2-4-1BB-CD3ζ) Biepitopic CAR, pCDCAR1 | VHH1-VHH2-4-1BB-CD3ζ | Lentiviral vector | T Cell | |||||
| XS-0922-ZP1203 | Anti-Claudin 6 (CB-P13) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Mouse | CB-P13 | Rat | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0922-ZP1407 | Anti-Claudin 6 (XP6) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | XP6 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-YF5806 | Anti-Claudin 6 (XW-286) h(CD28-CD3ζ) CAR, pAAV | Human | XW-286 | Mouse | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF5807 | Anti-Claudin 6 (XW-287) h(CD28-CD3ζ) CAR, pAAV | Human | XW-287 | Mouse | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF5808 | Anti-Claudin 6 (XW-288) h(CD28-CD3ζ) CAR, pAAV | Human | XW-288 | Mouse | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF5809 | Anti-Claudin 6 (XW-289) h(CD28-CD3ζ) CAR, pAAV | Mouse | XW-289 | Rat | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF5810 | Anti-Claudin 6 (XW-290) h(CD28-CD3ζ) CAR, pAAV | Human | XW-290 | Mouse | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF7650 | Anti-Claudin 6 (XW-290) h(CD28-41BB-CD3ζ) CAR, pAAV | Human | XW-290 | Mouse | scFv-CD28-41BB-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-0123-ZP266 | Anti-Claudin 6 (61D) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 61D | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP267 | Anti-Claudin 6 (89A) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 89A | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP268 | Anti-Claudin 6 (64A) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 64A | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP522 | Anti-Claudin 6 (CB-P13) h(scFv-CD3ε) TRuC, pCDTRC1 | Mouse | CB-P13 | Rat | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP827 | Anti-Claudin 6 (XP6) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | XP6 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0323-ZP266 | Anti-Claudin 6 (61D scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 61D | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP267 | Anti-Claudin 6 (89A scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 89A | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP268 | Anti-Claudin 6 (64A scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 64A | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP522 | Anti-Claudin 6 (CB-P13 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Mouse | CB-P13 | Rat | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP827 | Anti-Claudin 6 (XP6 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | XP6 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0923-LX116 | Anti-hClaudin 6 (CD28-41BB-CD3ζ) CAR-duplex CTLA4 pCDCAR1 Vector | Human | X9X-85 | scFv-CD28-41BB-CD3ζ-duplex CTLA4 | Lentiviral vector | T cell | CAR-T |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
